Sandoz obtains distribution rights for Proventil HFA generic

Sandoz has gained the in-licensing of commercial distribution rights to the brand and authorized generic of respiratory inhalation medicine Proventil HFA (albuterol sulfate) Inhalation Aerosol from Kindeva Drug Delivery, a global contract development and manufacturing organization supplying the product.

Sandoz’s albuterol sulfate authorized generic is immediately available.

“With the commercial distribution rights to the brand and authorized generic of Proventil HFA, we are excited to work to increase supply and help ensure patients who need albuterol have access to this important medicine,” said Keren Haruvi, Sandoz president. “This deal delivers on our strategy to grow our respiratory portfolio and brings us closer to our ambition to be the world’s leading and most valued generic company.”

Albuterol sulfate is used to treat patients four years and older suffering from bronchospasm, a condition where the muscular coat of the bronchial tubes contracts, resulting in a narrowing of the breathing airways. Exercise or other physical activities can also bring on symptoms in most people who have asthma and may occur either during or right after being active.

“We are pleased to partner with Sandoz on the distribution of the authorized generic of Proventil from our manufacturing site in Northridge, Calif.,” said Aaron Mann, CEO of Kindeva Drug Delivery. “Combining Kindeva’s long track record of formulating, developing and manufacturing complex combination drug products with the Sandoz legacy of successfully commercializing critical drug therapies will help more patients access this important medicine.”